The interest rate on borrowings. [Refer: Borrowings]

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name IFRS
-Number 7
-IssueDate 2023-01-01
-Paragraph 7
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_7&doctype=Standard
-URIDate 2023-03-23

+ Details

Name:	ifrs-full_BorrowingsInterestRate
Namespace Prefix:	ifrs-full_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.

+ References

No definition available.

+ Details

Name:	ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The nominal or face amount of a financial instrument, used to calculate payments made on that instrument.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name IAS
-Number 1
-IssueDate 2023-01-01
-Paragraph 112
-Subparagraph c
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_112_c&doctype=Standard
-URIDate 2023-03-23

+ Details

Name:	ifrs-full_NotionalAmount
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	na
Period Type:	instant

- Definition

The cash inflow from borrowings obtained. [Refer: Borrowings]

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Name IAS
-Number 7
-IssueDate 2023-01-01
-Paragraph 17
-Subparagraph c
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17_c&doctype=Standard
-URIDate 2023-03-23

+ Details

Name:	ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Aggregate amount to be received by the company, either in exchange for new shares of the Company or through the receipt of upfront or milestone payments, pursuant to the debt arrangement.

+ References

No definition available.

+ Details

Name:	iva_AggregateAmountToBeReceivedEitherInExchangeForNewSharesOfCompanyOrThroughReceiptOfUpfrontOrMilestonePayments
Namespace Prefix:	iva_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Exercise price of warrants issued, represented as a percentage of volume-weighted average price of the Company's shares.

+ References

No definition available.

+ Details

Name:	iva_ClassOfWarrantOrRightExercisePriceOfWarrantsAsPercentageOfVolumeWeightedAveragePriceOfCompanySShares
Namespace Prefix:	iva_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Exercise price per share or per unit of warrants or rights outstanding.

+ References

No definition available.

+ Details

Name:	iva_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
Namespace Prefix:	iva_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	instant

- Definition

Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.

+ References

No definition available.

+ Details

Name:	iva_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
Namespace Prefix:	iva_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

No definition available.

+ Details

Name:	iva_IfrsDebtInstrumentTerm
Namespace Prefix:	iva_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

The maximum gross proceeds from receivable upon exercise of warrants.

+ References

No definition available.

+ Details

Name:	iva_MaximumGrossProceedsReceivableUponExerciseOfWarrants
Namespace Prefix:	iva_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The amount of minimum upfront payments for out-licensing, partnership or royalty transaction.

+ References

No definition available.

+ Details

Name:	iva_MinimumUpfrontPaymentsForOutLicensingPartnershipOrRoyaltyTransaction
Namespace Prefix:	iva_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Number of sites operating under central IRB overseeing

+ References

No definition available.

+ Details

Name:	iva_NumberOfSitesOperatingUnderCentralIrbOverseeing
Namespace Prefix:	iva_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Number of warrants issued

+ References

No definition available.

+ Details

Name:	iva_NumberOfWarrantsIssued
Namespace Prefix:	iva_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Percentage of Company's share capital outstanding, issued as warrants by the entity.

+ References

No definition available.

+ Details

Name:	iva_PercentageOfCompanySShareCapitalOutstandingIssuedAsWarrants
Namespace Prefix:	iva_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Percentage of patients randomized in the main cohort

+ References

No definition available.

+ Details

Name:	iva_PercentageOfPatientsRandomizedInMainCohort
Namespace Prefix:	iva_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Percentage of share capital held by counterparty if all outstanding warrants are exercised

+ References

No definition available.

+ Details

Name:	iva_PercentageOfShareCapitalHeldByCounterpartyIfAllOutstandingWarrantsAreExercised
Namespace Prefix:	iva_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Shares issuable upon exercise of warrants.

+ References

No definition available.

+ Details

Name:	iva_SharesIssuableUponExerciseOfWarrants
Namespace Prefix:	iva_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Treatment period under study

+ References

No definition available.

+ Details

Name:	iva_TreatmentPeriodUnderStudy
Namespace Prefix:	iva_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Term of warrants.

+ References

No definition available.

+ Details

Name:	iva_WarrantsTerm
Namespace Prefix:	iva_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	ifrs-full_BorrowingsByNameAxis=iva_FinanceContractWithEuropeanInvestmentBankMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_BorrowingsByNameAxis=iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_BorrowingsByNameAxis=iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=iva_WarrantAgreementWithEuropeanInvestmentBankMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=iva_Nativ3PhaseIiiTrialOfLanifibranorInNonCirrhoticNashMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=iva_LegendPhaseIiaCombinationTrialWithLanifibranorAndEmpagliflozinInPatientsWithMashNashAndT2dMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=iva_IssuanceOfWarrantsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=iva_DrawdownOfBorrowingsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=iva_FirstApprovalFromCentralIrbOverseeingClinicalResearchInUnitedStatesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=iva_PresentationOfResultsFromStudyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Events after the reporting date (Details)								12 Months Ended
Events after the reporting date (Details)	Mar. 07, 2024	Jan. 18, 2024 EUR (€) shares	Jan. 04, 2024 EUR (€) € / shares shares	Dec. 08, 2022 EUR (€)	Nov. 28, 2022 € / shares shares	Aug. 03, 2022	May 16, 2022 EUR (€)	Dec. 31, 2023 shares	Dec. 31, 2022 EUR (€)	Mar. 28, 2024 shares	Jul. 01, 2022 EUR (€) shares
Events after the reporting date
Notional amount		€ 25,000,000
Subscription of borrowings									€ 30,209,000
Finance contract with EIB
Events after the reporting date
Notional amount							€ 50,000,000
Finance contract with EIB, first tranche (Tranche A)
Events after the reporting date
Subscription of borrowings				€ 25,000,000
Interest rate				8.00%			8.00%
Maturity term after the disbursement of the tranche				4 years			4 years
Aggregate amount to be received under the conditions precedent to the EIB Financing							€ 18,000,000
Finance contract with EIB, first tranche (Tranche A) \| Financial liabilities at amortized cost
Events after the reporting date
Notional amount				€ 25,000,000
Finance contract with EIB, second tranche (Tranche B)
Events after the reporting date
Notional amount									€ 25,000,000
Interest rate							7.00%
Maturity term after the disbursement of the tranche							3 years
Aggregate amount to be received under the conditions precedent to the EIB Financing							€ 70,000,000
Minimum upfront payments for out-licensing, partnership or royalty transaction							€ 10,000,000
Warrant agreement with the European Investment Bank
Events after the reporting date
Number of warrants issued \| shares					2,266,023			2,266,023
Percentage of company's share capital outstanding, issued as warrants					5.40%			5.20%
Exercise price of warrant \| € / shares					€ 4.0152
Number of shares per instrument \| shares											1
Warrant agreement with the European Investment Bank \| Finance contract with EIB
Events after the reporting date
Notional amount											€ 50,000,000
NATiV3 Phase III trial of lanifibranor in non-cirrhotic NASH
Events after the reporting date
Treatment period under study						168 days
LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D [Member]
Events after the reporting date
Treatment period under study	168 days
Issuance of warrants \| Finance contract with EIB
Events after the reporting date
Percentage of share capital held by counterparty if all outstanding warrants are exercised			10.30%
Issuance of warrants \| Finance contract with EIB, second tranche (Tranche B)
Events after the reporting date
Number of warrants issued \| shares			3,144,654
Percentage of company's share capital outstanding, issued as warrants			6.00%
Exercise price of warrant \| € / shares			€ 3.95
Exercise price of warrants as a percentage of volume-weighted average price of the Company's shares			95.00%
Term of warrants			12 years
Shares issuable upon exercise of warrants \| shares			3,144,654
Maximum gross proceeds			€ 12,421,383
Issuance of warrants \| Warrant agreement with the European Investment Bank \| Finance contract with EIB, first tranche (Tranche A)
Events after the reporting date
Number of shares per instrument \| shares										1.27
Drawdown of borrowings \| Finance contract with EIB
Events after the reporting date
Subscription of borrowings		25,000,000
Drawdown of borrowings \| Finance contract with EIB, first tranche (Tranche A)
Events after the reporting date
Aggregate amount to be received under the conditions precedent to the EIB Financing		€ 18,000,000
Drawdown of borrowings \| Finance contract with EIB, second tranche (Tranche B)
Events after the reporting date
Number of warrants issued \| shares		3,144,654
Subscription of borrowings		€ 25,000,000.0
Interest rate		7.00%
Maturity term after the disbursement of the tranche		3 years
Aggregate amount to be received under the conditions precedent to the EIB Financing		€ 70,000,000
Minimum upfront payments for out-licensing, partnership or royalty transaction		€ 10,000,000
First approval from the central IRB overseeing clinical research in the United States \| NATiV3 Phase III trial of lanifibranor in non-cirrhotic NASH
Events after the reporting date
Number of sites operating under central IRB overseeing	152
Percentage of patients randomized in the main cohort	60.00%
Presentation of results from study \| LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D [Member]
Events after the reporting date
Treatment period under study	168 days